More insights into the genetic variants of GFRAL—together with a more comprehensive knowledge about the control of the transcription and translation of GFRAL under disease conditions, as well as further explanations of GDF15-mediated effects beyond the AP/NTS—could be relevant for the development of novel pharmacological therapies for physical and mental disorders related to body image and food intake, such as eating disorders, cachexia and obesity. This evidence concerns the gene GFRAL and obesity due to melanocortin 4 receptor deficiency.